» Articles » PMID: 32195308

Laboratory Studies for Paroxysmal Nocturnal Hemoglobinuria, with Emphasis on Flow Cytometry

Overview
Journal Pract Lab Med
Specialty Biochemistry
Date 2020 Mar 21
PMID 32195308
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal hematopoietic stem cell disorder caused by somatic mutations in the gene, leading to the production of blood cells with absent or decreased expression of glycosylphosphatidylinositol-anchored proteins, including CD55 and CD59. Clinically, PNH is classified into three variants: classic (hemolytic), in the setting of another specified bone marrow disorder (such as aplastic anemia or myelodysplastic syndrome) and subclinical (asymptomatic). PNH testing is recommended for patients with intravascular hemolysis, acquired bone marrow failure syndromes and thrombosis with unusual features. Despite the availability of consensus guidelines for PNH diagnosis and monitoring, there are still discrepancies on how PNH tests are carried out, and these technical variations may lead to an incorrect diagnosis. Herein, we provide a brief historical overview of PNH, focusing on the laboratory tests available and on the current recommendations for PNH diagnosis and monitoring based in flow cytometry.

Citing Articles

Monitoring and Treatment of Paroxysmal Nocturnal Hemoglobinuria in Patients with Aplastic Anemia in Asia: An Expert Consensus.

Wong R, Jang J, Wong L, Kim J, Rojnuckarin P, Goh Y Int J Mol Sci. 2024; 25(22).

PMID: 39596227 PMC: 11594386. DOI: 10.3390/ijms252212160.


The Features of COVID-19's Course and the Efficacy of the Gam-COVID-Vac Vaccine in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Ptushkin V, Arshanskaya E, Vinogradova O, Kudlay D, Nikitin E Hematol Rep. 2023; 15(3):503-512.

PMID: 37754667 PMC: 10531158. DOI: 10.3390/hematolrep15030052.


A Case of Paroxysmal Cold Hemoglobinuria Possessing Moderate Paroxysmal Nocturnal Hemoglobinuria-Type Erythrocytes.

Sugimoto T, Masui E, Ohata S, Goto H, Tomita T, Hashimoto H Am J Case Rep. 2021; 22:e933102.

PMID: 34819489 PMC: 8630556. DOI: 10.12659/AJCR.933102.


Increasing Incidence and Prevalence of Acquired Hemolytic Anemias in Denmark, 1980-2016.

Hansen D, Moller S, Andersen K, Gaist D, Frederiksen H Clin Epidemiol. 2020; 12:497-508.

PMID: 32547241 PMC: 7250289. DOI: 10.2147/CLEP.S250250.

References
1.
Munoz-Linares C, Ojeda E, Fores R, Pastrana M, Cabero M, Morillo D . Paroxysmal nocturnal hemoglobinuria: a single Spanish center's experience over the last 40 yr. Eur J Haematol. 2014; 93(4):309-19. PMC: 4232878. DOI: 10.1111/ejh.12346. View

2.
Skubitz K, Kuroki M, Jantscheff P, Skubitz A, Grunert F . CD66b. J Biol Regul Homeost Agents. 2000; 13(4):242-3. View

3.
Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R . Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005; 106(12):3699-709. PMC: 1895106. DOI: 10.1182/blood-2005-04-1717. View

4.
Marinov I, Illingworth A, Benko M, Sutherland D . Performance Characteristics of a Non-Fluorescent Aerolysin-Based Paroxysmal Nocturnal Hemoglobinuria (PNH) Assay for Simultaneous Evaluation of PNH Neutrophils and PNH Monocytes by Flow Cytometry, Following Published PNH Guidelines. Cytometry B Clin Cytom. 2016; 94(2):257-263. DOI: 10.1002/cyto.b.21389. View

5.
Edberg J, Salmon J, Kimberly R . Functional capacity of Fc gamma receptor III (CD16) on human neutrophils. Immunol Res. 1992; 11(3-4):239-51. DOI: 10.1007/BF02919130. View